Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lonza Group Ag (OP:LZAGF)

684.64 +40.18 (+6.24%)
Streaming Delayed Price Updated: 9:30 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lonza Group Ag

News headline image
Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development ↗
Lonza unveils its "One Lonza" strategy, highlighting a new structure to streamline operations, strengthen CDMO leadership, and project 20% CER sales growth in 2025. 
Via Benzinga
News headline image
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B ↗
Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to... 
Via Benzinga
News headline image
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field ↗
 
Via Benzinga
News headline image
Charles River's Jim Foster Beat The Trauma Of Being CEO ↗
Think taking over the family business is easy? Charles River CEO Jim Foster might beg to differ. He's shown that being CEO comes with trauma. 
Via Investor's Business Daily
News headline image
Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses ↗
Moderna Inc (NASDAQ: MRNA) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children. It has entered... 
Via Benzinga
News headline image
Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually ↗
Moderna Inc (NASDAQ: MRNA) plans to produce up to 3 billion doses in 2022, doubling capacity at contract sites in Switzerland and Spain run by Lonza Group... 
Via Benzinga
News headline image
aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810 ↗
aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.